Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autoradiography and preclinical PET studies with radiolabeled asyn-44 and ACI-12589 for imaging α-synuclein.

Journal of Parkinson's disease·2026
Same author

Discovery of <i>N</i>-(6-Methoxypyridin-3-yl)quinoline-2-amine Derivatives for Imaging Aggregated α-Synuclein in Parkinson's Disease with Positron Emission Tomography.

Cells·2025
Same author

First-in-human PET neuroimaging of [<sup>18</sup>F]OXD-2314.

European journal of nuclear medicine and molecular imaging·2025
Same author

An inverse association of cerebral amyloid-β deposition and serum docosahexaenoic acid levels in cognitively normal older adults in Japan.

Journal of Alzheimer's disease : JAD·2025
Same author

The development of a PET radiotracer for imaging alpha synuclein aggregates in Parkinson's disease.

RSC medicinal chemistry·2025
Same author

Structure-Activity Relationships and Evaluation of 2-(Heteroaryl-cycloalkyl)-1<i>H</i>-indoles as Tauopathy Positron Emission Tomography Radiotracers.

Journal of medicinal chemistry·2025

Related Experiment Video

Updated: Apr 20, 2026

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
07:28

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

4.9K

The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.

William E Klunk1, Robert A Koeppe2, Julie C Price3

  • 1Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; Department of Neurology, University of Pittsburgh, Pittsburgh. PA, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 3, 2014
PubMed
Summary
This summary is machine-generated.

Standardizing amyloid PET imaging is crucial for Alzheimer's disease research. A new "Centiloid" scale unifies quantitative measures across different tracers and analysis methods for consistent results.

Keywords:
Amyloid imagingCentiloid scalePittsburgh compound BPositron emission tomographyStandardize

More Related Videos

Absolute Quantification of A&#946;1-42 in CSF Using a Mass Spectrometric Reference Measurement Procedure
08:40

Absolute Quantification of Aβ1-42 in CSF Using a Mass Spectrometric Reference Measurement Procedure

Published on: March 21, 2017

8.1K
Detecting Amyloid-&#946; Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
08:25

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Published on: April 19, 2021

4.2K

Related Experiment Videos

Last Updated: Apr 20, 2026

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
07:28

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

4.9K
Absolute Quantification of A&#946;1-42 in CSF Using a Mass Spectrometric Reference Measurement Procedure
08:40

Absolute Quantification of Aβ1-42 in CSF Using a Mass Spectrometric Reference Measurement Procedure

Published on: March 21, 2017

8.1K
Detecting Amyloid-&#946; Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
08:25

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Published on: April 19, 2021

4.2K

Area of Science:

  • Neurology
  • Nuclear Medicine
  • Biomarker Research

Background:

  • Amyloid PET imaging, using tracers like PiB-PET, provides consistent qualitative Alzheimer's disease findings.
  • Quantitative outcome measures of tracer retention show considerable variability across centers and methods.
  • Inconsistent quantitative data hinders direct comparison and meta-analysis of amyloid PET studies.

Purpose of the Study:

  • To standardize quantitative amyloid imaging measures for improved consistency and comparability.
  • To develop a universal scaling method for diverse amyloid PET tracers and analysis techniques.
  • To establish a reliable quantitative framework for Alzheimer's disease biomarker research.

Main Methods:

  • Development of a "standard" analysis method for PiB PET data.
  • Creation of a scaling method to convert results from various analysis techniques and tracers to a unified scale.
  • Anchoring the scale using young healthy controls (≤ 45 years) and typical Alzheimer's disease patients.

Main Results:

  • Introduction of the "Centiloid" scale, ranging from 0 to 100.
  • The Centiloid scale provides a standardized unit for quantitative amyloid retention.
  • Enables scaling of non-standard PiB PET analysis and other amyloid tracers to a common metric.

Conclusions:

  • The Centiloid scale offers a robust solution to the variability in quantitative amyloid PET imaging.
  • Standardization facilitates more reliable comparisons of study results and meta-analyses.
  • This unified approach will advance Alzheimer's disease diagnosis and therapeutic monitoring.